Extracellular Vesicle Checkpoint Protein Assessment for Cancer Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current checkpoint inhibitor therapies for cancer treatment have limited response rates and short-lived responses due to the release of checkpoint proteins on extracellular vesicles by tumors, overwhelming the immune system and bypassing therapeutic effects.
Innovation Solution
A method involving the assessment of extracellular vesicles in biological samples before and after checkpoint inhibitor therapy to identify changes in checkpoint protein levels, allowing for the administration of alternative treatments or combination therapies based on specific marker and protein levels, such as PD-L1, CD155, and TIGIT, to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint inhibitor therapy is administered to treat cancer, then immune response against tumor is enhanced, but response rate remains low and responses are short-lived due to overwhelming checkpoint proteins released by tumors
Solution Approach 1:
The patent extracts and measures specific checkpoint proteins (PD-L1, PD-L2, B7H3, B7H4) from extracellular vesicles in patient biological samples. By isolating and quantifying these harmful factors, the method identifies patients whose checkpoint protein levels indicate they will not respond to therapy, thereby excluding them from treatment and improving overall response rates.
Solution Approach 2:
The patent performs preliminary measurement of checkpoint protein levels on extracellular vesicles before administering checkpoint inhibitor therapy. This pre-treatment assessment predicts patient response, allowing clinicians to avoid administering ineffective therapy to non-responders and to select appropriate patients who are most likely to benefit from the treatment.
2Duration of action of stationary object
If checkpoint inhibitor therapy is administered, then some patients experience tumor mass decrease, but responses are often partial or short-lived
Solution Approach 1:
The patent performs preliminary measurement of checkpoint protein levels on extracellular vesicles before administering checkpoint inhibitor therapy. This pre-treatment assessment predicts patient response, allowing clinicians to identify patients likely to have durable responses versus those with partial or short-lived responses, thereby improving treatment selection and outcomes.
Solution Approach 2:
The patent establishes a feedback mechanism where checkpoint protein levels on extracellular vesicles are measured to predict and monitor treatment response. This information feeds back into treatment decision-making, allowing for personalized therapy selection and potential adjustment of treatment strategies based on predicted response duration and consistency.
3Productivity
If checkpoint inhibitor therapy is administered, then immune checkpoint responses are activated, but only a minority of patients respond to the therapy
Solution Approach 1:
The patent replaces traditional mechanical or visual assessment methods with a biochemical measurement system. By using assays to detect and quantify checkpoint proteins (PD-L1, PD-L2, B7H3, B7H4) on extracellular vesicles, the method objectively identifies patient responsiveness potential, thereby increasing the number of patients who can be accurately selected for effective therapy.
Solution Approach 2:
The patent uses extracellular vesicles as an intermediary to assess checkpoint protein levels. These vesicles serve as a measurable proxy for tumor immune interaction status, providing an indirect but reliable indicator of patient response likelihood without requiring direct observation of complex immune cell-tumor interactions.
Data Source
AI summary
The present disclosure provides methods for predicting and thereby treating cancer or increasing the efficacy of an anti-cancer medication, in part by measuring checkpoint proteins on extracellular vesicles released from non-cancer cells. These checkpoint proteins promote cancer progression and/or compensate for the loss of signal from the checkpoint proteins being inhibited by the checkpoint inhibitory therapy. Compositions and methods of treatment are also provided.